GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Twist Bioscience Corp (FRA:0ME) » Definitions » EV-to-EBIT

Twist Bioscience (FRA:0ME) EV-to-EBIT : -7.88 (As of May. 28, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Twist Bioscience EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Twist Bioscience's Enterprise Value is €1,392.2 Mil. Twist Bioscience's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was €-176.7 Mil. Therefore, Twist Bioscience's EV-to-EBIT for today is -7.88.

The historical rank and industry rank for Twist Bioscience's EV-to-EBIT or its related term are showing as below:

FRA:0ME' s EV-to-EBIT Range Over the Past 10 Years
Min: -70.74   Med: -8.82   Max: -1.8
Current: -8.31

During the past 9 years, the highest EV-to-EBIT of Twist Bioscience was -1.80. The lowest was -70.74. And the median was -8.82.

FRA:0ME's EV-to-EBIT is ranked worse than
100% of 106 companies
in the Medical Diagnostics & Research industry
Industry Median: 20.705 vs FRA:0ME: -8.31

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Twist Bioscience's Enterprise Value for the quarter that ended in Mar. 2025 was €1,995.5 Mil. Twist Bioscience's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was €-176.7 Mil. Twist Bioscience's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was -8.86%.


Twist Bioscience EV-to-EBIT Historical Data

The historical data trend for Twist Bioscience's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Twist Bioscience EV-to-EBIT Chart

Twist Bioscience Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only -22.85 -31.76 -6.93 -4.54 -11.86

Twist Bioscience Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.37 -12.20 -11.86 -13.12 -11.40

Competitive Comparison of Twist Bioscience's EV-to-EBIT

For the Diagnostics & Research subindustry, Twist Bioscience's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Twist Bioscience's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Twist Bioscience's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Twist Bioscience's EV-to-EBIT falls into.


;
;

Twist Bioscience EV-to-EBIT Calculation

Twist Bioscience's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1392.164/-176.744
=-7.88

Twist Bioscience's current Enterprise Value is €1,392.2 Mil.
Twist Bioscience's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-176.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Twist Bioscience  (FRA:0ME) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Twist Bioscience's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2025 ) =EBIT / Enterprise Value (Q: Mar. 2025 )
=-176.744/1995.45699
=-8.86 %

Twist Bioscience's Enterprise Value for the quarter that ended in Mar. 2025 was €1,995.5 Mil.
Twist Bioscience's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-176.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Twist Bioscience EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Twist Bioscience's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Twist Bioscience Business Description

Traded in Other Exchanges
Address
681 Gateway Boulevard, South San Francisco, CA, USA, 94080
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.

Twist Bioscience Headlines

No Headlines